Fritextsökning
Artiklar per år
Innehållstyper
-
“We develop vaccines no one else is developing”
Vaccines delivered via patches rather than injections. Future solutions could fundamentally reshape global health. Meet the man leading efforts to distribute vaccines where the need is greatest.
-
GLP-1 profile leaves Novo Nordisk after 36 years
Lotte Bjerre Knudsen, one of the key figures behind Novo Nordisk’s success in obesity medicines, is leaving the company after more than three decades.
-
GSK eyes blockbuster potential – plans five new trials
GSK sees blockbuster potential in its experimental drug candidate Mo-rez. Early trial results suggest the treatment may shrink tumours in patients with advanced and hard-to-treat gynaecological cancers.
-
Sprint Bioscience bygger molekylerna som ska bli nya läkemedel
I Sprint Biosciences labb i Flemingsberg i Huddinge skapas molekyler som ingen annan tidigare byggt. Bolaget har specialiserat sig på preklinisk läkemedelsutveckling, och har i flera fall nått fram till affärer och partnerskap med större läkemedelsbolag.
-
Sprint Bioscience builds the molecules that will become new medicines
In Sprint Bioscience’s laboratory in Flemingsberg, Huddinge, molecules are being created that no one has ever built before. The company specializes in preclinical drug development and has, in several cases, succeeded in securing deals and partnerships
-
“Ozempic babies” – myth or reality?
Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.
-
A food-based strategy to stop gut infections early
Most gastrointestinal infections are treated only after symptoms have already developed. Researcher Andreas Hougaard Laustsen-Kiel aims to reduce risk earlier by adding specially engineered binding proteins directly to food and animal feed.
-
Thermo Fisher Expands in Sweden – “We Are Sending a Clear Message”
The American life science giant Thermo Fisher Scientific has inaugurated a new distribution center in Uppsala. “By investing in increasing our capacity as well as our R&D here in Uppsala, we are building resilience for decades, not quarters,” says Santhosh Nair of Thermo Fisher.
-
National cord blood bank resumes collection
The collection of umbilical cord blood is now resuming during planned caesarean sections at Östra Hospital in Gothenburg. The blood remaining in the placenta and umbilical cord after birth contains stem cells that can be used to treat conditions including leukaemia and severe immunodeficiency disorders.
-
We are expanding our English-language coverage
Over a period of four weeks, one of Life Science Sweden's regular daily newsletters is being published entirely in English. The aim is to meet increasing demand and evaluate reader interest. (Swedish version below)
-
International medical graduates leave Sweden in high numbers
Three years after completing their studies, 46 percent of international doctoral students who graduated in the medical field had left the country. This is shown in Statistics Sweden’s (SCB) analysis of researchers who graduated between 2017 and 2020.
-
More than 150 jobs cut as Merck scales back vaccin production
Merck & Co, known as MSD in Europe, is hitting the brakes following a sharp decline in demand for its HPV vaccine Gardasil. Production at its facility in Durham, North Carolina, is now being halted, with more than 150 employees facing redundancy.
-
Samuel Lagercrantz: ”Obesity, blockbusters and Swedish biotech”
The development of technologies to bypass the blood-brain barrier is particularly exciting right now, as it holds the potential to unlock new treatments for a range of neurological diseases, according to Samuel Lagercrantz.
-
Anna Törner: ”Drug prices – an important driver of innovation”
We live under the illusion that no price is too high when it comes to health, but that simply isn’t true, writes Anna Törner.
-
End of bone‑sawing? New laser cuts to record depths
Saw, drill and chisel are a bone surgeon’s best friends today – but soon the laser may also find its place in that toolbox. Researchers in Switzerland have discovered a method for cutting significantly deeper and faster with a surgical laser than has previously been possible.
-
Lost in the recruitment process? How hiring really works today
As recruitment becomes increasingly automated, candidates are expected to adapt to both human and algorithmic decision-making. Career coach Tina Persson outlines why the process feels unfair – and how jobseekers can approach it more strategically.
-
Novo Nordisk strengthens board after turbulent year
Changes to Novo Nordisk’s board continue. Following last year’s sweeping restructuring, the Danish obesity drugmaker is now nominating two new directors with extensive experience in the pharmaceutical industry.
-
New antibody aims to slow kidney damage – “It’s kind of cool”
For 25 years, Marie Jeansson has studied the kidney and its blood vessels. She is now working on developing a drug intended to slow down chronic kidney disease.
-
A healthy society requires more than a new pill
Sarah Lidé on how medicines are essential – but a sustainable approach to healthy societies also depends on prevention and behavioural change
-
Asgard teaches tumours to self‑destruct – moving closer to clinical trials
Swedish biotech Asgard Therapeutics not only has an evocative name, but also a remarkably exciting approach to cancer treatment: getting tumour cells to reprogram themselves so that they become visible to the body’s immune system.
-
FDA leaders seek to scrap two-study requirement
A single pivotal study may be sufficient to secure approval for a new medicine in the United States. That is the message delivered by FDA Commissioner Marty Makary and the agency’s medical and scientific chief, Vinay Prasad, in an article in the New England Journal of Medicine.
-
Björn Arvidsson: ”As uncertainty grows, clarity becomes a strength”
Sweden has all the prerequisites to be a strong life science nation. But in a time of geopolitical tension, shorter value chains and growing demands for resilience, it is no longer enough to be “good at many things”, Björn Arvidsson writes in a column.
-
“BioArctic is Leqembi, but also much more”
What once began as a small Swedish biotech company has grown into a fully fledged pharmaceutical company with global reach. At the helm is Gunilla Osswald, who joined early on and is now leading BioArctic into its next era.
-
Genovis ramps up in ADC technology: “An area where we’re seeing very strong interest”
With new products and an expanded licensing agreement in hand Genovis now has a partly new focus for its operations: ADCs – or antibody‑drug conjugates.
BREAKING